life scienc tool diagnost
exceed estim weaker revenu off-set better
profit lower top-line guidanc vs consensu
rais low end ep guidanc rang
midpoint vs con ep move
reflect beat target price stand monument
chang model
revenu book lighter plan profit prevail revenu rose
plan cc clinic research revenu
basi behind plan data solut increas
vs estimate recov declin net new busi nnb
rel flat vs estimate repres net btb
slightli estimate end backlog rose
billion backlog burn sequenti unchang cancel rate
bp q/q histor rang gross margin improv
bp despit continu hire sg margin declin bp
ebitda margin rose bp plan use million cash vs
million cash reserv stand million ttm cash
share may eas encourag latest oper
upsid share may ebb disappoint top-line experi lower
expect nnb albeit rel tough comp trim
cc revenu growth target view
previous impli revenu ramp aggress boost ep
rang focu call like book trend
times/delay profit dynam ramp bench better util
maintain posit bia strateg partnership
comprehens full/fsp offer support growth ahead peer
longer term risk demand sponsor consolid
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc contract research organ
servic biotechnolog pharmaceut industri
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario assum meaning
acceler profit margin nt faster materi near term
revenu gener recent award addit strateg
partnership predic continu healthi industri dynam
deceler profit margin less revenu gener recent
award expect project cancel client loss custom
consolid slowdown outsourc demand
 close
charl martineau pm univers toronto figur backlog convers remain slightli industri averag
compani mention price
